Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxity

Schizophrenia Research

Volumn 21, Issue 1, 1996, Pages 33-37

  Farber, Nuri B ^a   Foster, John ^a   Duhan, Nadine L ^a   Olney, John W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clozapine; MK 801; Neurotoxicity; NMDA antagonists; Novel antipsychotics; Olanzapine; Phencyclidine; Schizophrenia

Indexed keywords

AMOXAPINE; CLOZAPINE; DIZOCILPINE; FLUPERLAPINE; GLUTAMATE RECEPTOR; HALOPERIDOL; KETAMINE; LOXAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; PHENCYCLIDINE; THIORIDAZINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR BLOCKING; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030608074     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/0920-9964(96)00024-2     Document Type: Article

References (25)

1. Beasley, C., Tollefson, G., Tran, P., Satterlee, W., Sanger, T. and Hamilton, S. (1996) Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111-123.
2. Bolden, C., Cusack, B. and Richelson, E. (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 260, 576-580.
3. Corso, T.D., Wozniak, D.F., Sesma, M.A. and Olney, J.W. (1994) Neuron necrotizing properties of phencyclidine. Soc. Neurosci. Abstr. 20, 1531.
4. Coward, D.M. (1993) The pharmacology of clozapine-like, atypical antipsychotics. In: T.R.E. Barnes (Ed.), Antipsychotic drugs and their side-effects. Academic Press, London, pp. 27-44.
5. Domino, E.F. and Luby, E.D. (1981) Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: E.F. Domino (Ed.), PCP (Phencyclidine): Historical and Current Perspectives. NPP Books, Ann Arbor, pp. 401-418.
6. Ellison, G. and Switzer, R.C. (1993) Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 5, 17-20.
7. Ellison, G. (1994) Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5, 2688-2692.
8. Farber, N.B., Price, M.T., Labruyere, J., Nemnich, J., St Peter, H., Wozniak, D.F. and Olney, J.W. (1993a) Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiatry 34, 119-121.
9. Farber, N.B., Price, M.T., Labruyere, J., Nemnich, J., St. Peter, H. and Olney, J.W. (1993b) Protection against NMDA antagonist neurotoxicity by clozapine and related analogs correlates with antipsychotic efficacy. Soc. Neurosci. Abstr. 19, 384.
10. Farber, N.B., Wozniak, D.F., Price, M.T., Labruyere, J., Huss, J., St Peter, H. and Olney, J.W. (1995) Age specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol. Psychiatry 38, 788-796.
11. Fischer-Cornelssen, K.A. (1984) Fluperlapine in 104 Schizophrenic Patients. Arzneim-Forsch. 34(1a), 125-130.
12. Fix, A.S., Horn, J.W., Wightman, K.A., Johnson, C.A., Long, G.G., Storts, R.W., Farber, N., Wozniak, D.F. and Olney, J.W. (1993) Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123, 204-215.
13. Fix, A.S., Wozniak, D.F., Truex, L.L., McEwen, M., Miller, J.P. and Olney, J.W. (1995) Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Res. 696, 194-204.
14. Grotta, J., Clark, W., Coull, B., Pettigrew, L.C., Mackay, B., Goldstein, L.B., Murphy, D. and LaRue, L. (1995) Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase Ha randomized trial. Stroke 26, 602-605.
15. Herrling, P. (1994) D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from animal models and first results in humans. Neuropsychopharmacology 10 (3S/Part 1), 591S.
16. Javitt, D.C. and Zukin, S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
17. Kristensen, J.D., Svensson, B. and Gordh, T., Jr. (1992) The NMDA receptor-antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 51, 249-253.
18. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B., Jr. and Charney, D.S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214.
19. Lodge, D., Aram, J.A., Church, J., Davies, S.N., Martin, D., O'Shaughnessey, C.T. and Zeman, S. (1987) Excitatory amino acids and phencyclidine-like drugs. In: T.P. Hicks, D. Lodge and H. McLennan (Eds.), Excitatory amino acid transmission. Alan R. Liss Inc., New York, pp. 83-90.
20. Olney, J.W., Labruyere, J. and Price, M.T. (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244, 1360-1362.
21. Olney, J.W., Labruyere, J., Wang, G., Wozniak, D.F., Price, M.T. and Sesma, M.A. (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science 254, 1515-1518.
22. Olney, J.W. and Farber, N.B. (1995) Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52, 998-1007.
23. Svensson, T.H., Mathe, J.M. andersson, J.L., Nomikos, G.G. and Hildebrand, B.E. (1995) Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoreceptor antagonism. J. Clin. Psychopharm. 15, 11S-18S.
24. Tandon, R. and Greden, J.F. (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch. Gen. Psychiatry 46, 745-753.
25. Tandon, R., Shipley, J.E., Greden, J.F., Mann, N.A., Eisner, W.H. and Goodson, J.A. (1991) Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophr. Res. 4, 23-30.